Research programme: Burkholderia cepacia infections - Demegen
Latest Information Update: 25 Feb 2008
At a glance
- Originator Demegen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Burkholderia cepacia infections
Most Recent Events
- 27 Jun 2003 Suspended - Preclinical for Burkholderia cepacia infections in USA (unspecified route)
- 07 Nov 2001 Preclinical development for Burkholderia cepacia infections in USA (Unknown route)